We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Medicover Ab | LSE:0RPS | London | Ordinary Share | SE0009778848 | MEDICOVER ORD SHS CLASS B |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 81.20 | 79.20 | 83.20 | 2,215 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Medical Laboratories | 1.75B | 17.6M | 0.2412 | 336.65 | 5.93B |
STOCKHOLM, Feb. 11, 2022 /PRNewswire/ --
Fourth quarter
Full year
REVENUE AND EARNINGS
€ millions (€m) | Q4 2021 | Q4 2020 | Growth | FY 2021 | FY 2020 | Growth |
Revenue | 376.3 | 297.7 | 26% | 1,377.4 | 997.8 | 38% |
Operating profit (EBIT) | 41.6 | 29.9 | 39% | 159.4 | 61.3 | 160% |
Operating profit margin | 11.1% | 10.1% | 11.6% | 6.1% | ||
Net profit | 28.4 | 18.8 | 51% | 106.6 | 27.3 | 290% |
Net profit margin | 7.6% | 6.3% | 7.7% | 2.7% | ||
Basic/diluted earnings per share, € | 0.186 | 0.123 | 51% | 0.686 | 0.182 | 277% |
EBITDA | 75.1 | 53.1 | 42% | 270.4 | 157.5 | 72% |
EBITDA margin | 20.0% | 17.8% | 19.6% | 15.8% | ||
EBITDAaL | 56.9 | 41.2 | 38% | 210.8 | 108.5 | 94% |
EBITDAaL margin | 15.1% | 13.9% | 15.3% | 10.9% | ||
EBITA | 45.9 | 32.7 | 41% | 171.2 | 76.9 | 123% |
EBITA margin | 12.2% | 11.0% | 12.4% | 7.7% |
Definition and reconciliation of alternative performance measures are available at www.medicover.com/financial-information.
This interim report has not been subject to review by the Company's auditor.
This is information that Medicover AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication through the agency of the contact person set out below at 7.45 (CET) on 11 February 2022. This year-end report and other information about Medicover is available at medicover.com.
For full report, see attached pdf.
Financial Calendar
Annual report week 13
Interim report January-March 27 April
Annual general meeting 27 April
Interim report April-June 22 July
Interim report July-September 3 November
For further information, please contact:
Hanna Bjellquist, Head of Investor Relations
Phone: +46 70 303 32 72
E-mail: hanna.bjellquist@medicover.com
Conference call: A conference call for analysts and investors will be held today at 09.30 CET. To listen in please register here. To ask questions please dial in and use code: 4597901
SE: +46 (0)8-566 184 67
DE: +49 (0) 305 200 2085
UK: +44 (0) 2071 928 338
US: +1 646 741 3167
Medicover is a leading international healthcare and diagnostic services company and was founded in 1995. Medicover operates a large number of ambulatory clinics, hospitals, specialty-care facilities,laboratories and blood-drawing points and the largest markets are Poland and Germany. In 2020, Medicover had revenue of EUR 998 million and more than 32,000 employees. For more information, go to www.medicover.com
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/medicover/r/year-end-report-january-december-2021,c3504433
The following files are available for download:
https://mb.cision.com/Main/15662/3504433/1533511.pdf | Year-end report 2021 |
Copyright 2022 PR Newswire
1 Year Medicover Ab Chart |
1 Month Medicover Ab Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions